近年來中國的各個產業都飛速的在成長，欲領先世界各國的企圖明顯可見。根據中國近期於國內的政策改革以及在國際上的表現，醫藥產業將是繼紅色供應鏈崛起後，中國大力推展的重點產業之一，且學名藥的發展是中國政府首要的整頓對象。藥品研發工作是醫藥產業的根源，而委託研究機構 (CRO) 是藥品研發的各個角色中非常重要且不可或缺的ㄧ環。台灣的CRO產業相對於中國發展較早且已進入成熟階段，如何把握時機進入中國起飛的順流，實為台灣CRO公司值得深思及探討的議題。
本論文以單一個案研究法，以美商QPS集團於台灣設立的子公司昌達生化科技股份有限公司 (QPS Taiwan) 為例，以其學名藥的三大核心服務：藥學研究、試驗監察暨醫院管理及實驗室分析檢測服務，根據折衷理論 (Dunning, 1980 & 1988) 來評估CRO公司進入中國市場的方式，並於最後進行進入條件的分析與建議。

China is growing rapidly among different industries in recent years, and her intension to become the world leader is very obvious. According to China’s regulation reforming and performance on the international stage, pharmaceutical industry will be the next star industry of China after the red supply chain, and within the industry, generic drug will be the priority reforming target of Chinese government.
Drug development is the key source of pharmaceutical industry, and CRO is one of the major players in drug development. CRO industry in Taiwan is developed earlier than it is in China, and it has already drove to maturity. How to seize the opportunity to join the success downstream is truly an issue worth discussing and planning for Taiwanese CROs.
QPS Taiwan is a subsidiary of the American company, QPS Holdings, LLC. Take QPS Taiwan as an example, a single case study method is used to analyze entry strategies of CRO firms to China Market. Based on “The Eclectic Theory of International Production (Dunning, 1980 & 1988)”, QPS Taiwan and its three core services of the generic drug development were evaluated: clinical pharmacology, clinical monitoring & site management, and bioanalytical services. Concluded suggestions for entry strategies are summarized at the end of this research.

摘要 ……………………………………………………………………………… I
Abstract ………………………………………………………………………… II
誌謝詞 …………………………………………………………………………… III
目錄 ……………………………………………………………………………… IV
圖表目錄 ………………………………………………………………………… V
第一章 緒論 …………………………………………………………………… 1
1.1 研究背景 ………………………………………………………… 1
1.2 研究動機與目的 ………………………………………………… 5
第二章 文獻回顧 …………………………………………………………… 6
2.1 國際市場進入 - 折衷理論 ……………………………………… 6
第三章 研究方法 ……………………………………………………………… 8
3.1 研究範圍與方法 ………………………………………………… 8
3.2 研究流程與架構 ………………………………………………… 9
3.3 資料蒐集方式 …………………………………………………… 10
第四章 個案介紹 ……………………………………………………………… 11
4.1 藥品開發流程 …………………………………………………… 11
4.2 委託研究機構 (CRO) 簡介與市場概況 ……………………… 17
4.3 QPS Taiwan簡介 ……………………………………………… 21
第五章 QPS Taiwan 進入中國市場的分析 ………………………………… 24
5.1 所有權優勢分析 ………………………………………………… 24
5.2 區位優勢分析 …………………………………………………… 27
5.3 內部化優勢分析 ………………………………………………… 30
5.4 QPS Taiwan優勢及進入方式總整理…………………………… 33
第六章 結論與討論 …………………………………………………………… 34
6.1 結論 …………………………………………………………… 34
6.2 討論 …………………………………………………………… 35
6.3 未來研究方向 ………………………………………………… 37
參考文獻 ………………………………………………………………………… 38

Cheryl & Ein (2014)。藥品開發上市攻防戰─專利法規。股感知識庫。2014年11月14日。取自 https://www.stockfeel.com.tw/%e5%b0%88%e5%88%a9%e6%b3%95%e8%a6%8f/
王柏豪 (2015)。銳變CRO 2015生技"影武者"。環球生技月刊，2015 1月號。取自 http://www.gbimonthly.com/v1_2015/v1coverstory_2015_00.html
刘映 (2017)。仿制药一致性评价进入全面监督评价阶段 2018年前完成289个品种。新华网。2017年2月17日。取自 http://www.xinhuanet.com/health/2017-02/17/c_1120484085.htm
洪世章(2016, Jun)。創新六策。47-82。
陳恒德 (2017, Jun 14)。中國大陸藥品監管法規大破大立 台灣可借鑑。經濟日報，2017年6月14日。取自 https://money.udn.com/money/story/10164/2524811
劉怡媛、吳貞和 (2010)。服務業海外市場進入策略：機構理論觀點。亞東學報，3 0，219~228。
張蕙娟、林盈妤 (2014, Jun 2)。品牌圍城心法－全球學名藥產業發展。品牌好報，42。取自 http://www.bpaper.org.tw/strategy/%e5%85%a8%e7%90%83%e5%ad%b8%e5%90%8d%e8%97%a5%e7%94%a2%e6%a5%ad%e7%99%bc%e5%b1%95/
2017我国仿制药市场规模或接近5000亿。中国制药网。2017年3月3日。取自http://www.zyzhan.com/news/Detail/63025.html
人力资源社会保障部关于印发国家基本医疗保险、工伤保险和生育保险药品目录（2017年版）的通知。中華人民共和國人力資源和社會保障部。人社部发〔2017〕15号。2017年2月21日。取自http://www.mohrss.gov.cn/yiliaobxs/YILIAOBXSzhengcewenjian/201702/t20170223_266775.html
中国CFDA成为ICH正式成员意味着什么。中國醫藥創新促進會。2017年6月2日。取自 http://www.phirda.com/newsinfo.aspx?id=17452
中國大陸CFDA正式宣布成為國際醫藥法規協合會(ICH)成員。生策會。2017年6月20日。取自 https://ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0orsvwy6uc8yonh9
关于印发控制公立医院医疗费用不合理增长的若干意见的通知。中國政府網。国卫体改发〔2015〕89号。2015年11月6日。取自 http://www.nhfpc.gov.cn/tigs/s3577/201511/0038da2bf8fe43d69511fb675e205d37
国务院办公厅关于进一步改革完善药品 生产流通使用政策的若干意见。中華人民共和國中央人民政府。国办发〔2017〕13号。2017年2月9日。
国务院办公厅关于印发药品上市许可 持有人制度试点方案的通知。中華人民共和國中央人民政府。国办发〔2016〕41号。2016年6月6日。
國際生產折衷理論。華人百科。取自https://www.itsfun.com.tw/%E5%9C%8B%E9%9A%9B%E7%94%9F%E7%94%A2%E6%8A%98%E8%A1%B7%E7%90%86%E8%AB%96/wiki-9192276-6919056
Bauerschmidt, A.D. & Gillespie, S.K. (1985), "Common factors underlying barriers to export: studies in the U.S. paper industry", Journal of International Business Studies, 16 (3): 111-123. Retrieved from https://www.jstor.org/stable/154400?seq=1#page_thumbnails_tab_contents
Bill Wang, & Alistair Davidson (2017). “An overview of major reforms in China’s regulatory environment” [Electronic version]. Regulatory Rapporteur, Vol 14, No 7/8, 5-9.
BioSpectrum (2017, June 2). “APAC is the fastest growing market for CRO industry”. BioSpectrum Asia Edition. Retrieved from https://www.biospectrumasia.com/opinion/39/8996/apac-is-the-fastest-growing-market-for-cro-industry.html
Blake, Gregg & Fagan, Daniel, Ph.D. (2017, Jun). “CRO Market Analysis”. Brocair Partners: Analysis of the CRO Market. June 2017.
Fassbendar, Melissa (2017, March 6), “CRO market in Asia to see significant increase through 2020”. Oursourcing-pharma.com. Retrieved from https://www.outsourcing-pharma.com/Article/2017/03/06/CRO-market-in-Asia-to-see-significant-increase-through-2020
Davidson, H.W. (1982), “Global strategy management”, New York: John Wiley & Sons.
Dunning, J.H. (1980), "Toward an eclectic theory of international production: some empirical tests", Journal of International Business Studies, 11, 9-31.
Dunning, J.H. (1988), "The eclectic paradigm of international production: a restatement and some possible extensions", Journal of International Business Studies, 19, 1-31.
Gatignon, H. and Anderson, E. (1988), “The multinational corporation’s degree of control over foreign subsidiaries: an empirical test of a transaction cost explanation”, Journal of Law, Economics and Organization, 4, 305-336.
Goodnow, J.D. (1985), “Developments in international mode of entry analysis”, International Marketing Review, Autumn, 17-30.
Looney, William (2016, July 26). “ Pharm Exec’s Top 50 Companies 2016”. Pharmaceutical Executive, Volume 36, issue 6. Retrieved from http://www.pharmexec.com/2016-pharm-exec-50
Palepu, Krishna, and Carin-Isabel Knoop. "Novartis' Sandoz: Between Generics and Pharma." Harvard Business School Case 114-033, March 2014.
Root, F.R. (1987), Foreign market entry strategies, New York: AMACOM.
Sagonowsky, Eric (2017, May 16). “The top 15 generic drug makers by 2016 revenue”. FiercePharma, Retrieved from https://www.fiercepharma.com/special-report/top-15-generic-drugmakers-2016
Scherer F.M. (2011, December). “R&D Costs and Productivity in Biopharmaceuticals”. Harvard Kennedy School. 2-14.
Zhang, Jin (2017, October 30). “The Chinese CRO market is predicted to reach $100 billion in 2020”. Retrieved from http://thefierceconsultant.com/chinese-cro-market-reach-100-billion/
“2017 Biopharmaceutical Industry Profile”. PhRMA.
“Clinical Monitor Turnover Rates, Salaries Continue to Climb”. The Association of Clinical Research Professionals, 2017, November 3. Retrieved from https://www.acrpnet.org/2017/11/03/clinical-monitor-turnover-rates-salaries-continue-climb/
“Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023”. Reportsnreports, February 2018.
“Large molecules enjoy greater success rates than small”. Manufacturing Chemist. 2016, September 16. Retrieved from https://www.manufacturingchemist.com/news/article_page/Large_molecules_enjoy_greater_success_rates_than_small/120954
“Step 2: Preclinical Research”. U.S. Food and Drug Administration. 2018, January 4. Retrieved from https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405658.htm
“The Drug Development Process”. U.S. Food and Drug Administration. 2018, January 4. Retrieved from https://www.fda.gov/ForPatients/Approvals/Drugs/default.htm
“Top 10 Fastest-Growing industries”. IBISWorld. Social Report, April 2012, 2.
“Why We Need Generic Medicines: A series on the role of Generic Medicines Part 2”, IMS Health.